Asparkam tab. # 56 Renewal
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
56
Minimum age from
18 years
pharmachologic effect
The mechanism of action of the drug Asparkam is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space. Magnesium activates sodium-potassium-ATPase, removing sodium ions from the cell and returning potassium ions
reduces the concentration of sodium and prevents its exchange for calcium in the smooth muscles of blood vessels, lowering their resistance.
Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc. Both ions support the polarization of cell membranes.
The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle.
Due to magnesium ions, it participates in the processes of energy intake and consumption, normalizes membrane permeability, neuromuscular conductivity, DNA and RNA synthesis, cell growth, cell division, oxygen assimilation and phosphate synthesis.
Pharmacokinetics
Potassium and magnesium ions are rapidly absorbed and distributed throughout all body tissues.
About 30% of magnesium in plasma forms complex compounds with proteins.
The excretion of potassium and magnesium occurs mainly with urine, in small quantities - with feces, sweat, tears, etc. In renal failure, the excretion of potassium and magnesium ions may slow down.
Indications
To eliminate the deficiency of potassium and magnesium
as an aid for various manifestations of coronary heart disease, including acute myocardial infarction
chronic circulatory failure
heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).
Contraindications
Hypersensitivity to the drug Asparkam,
hyperkalemia,
hypermagnesemia,
acute and chronic renal failure,
insufficiency of the adrenal cortex,
atrioventricular block II and III degree,
cardiogenic shock,
oliguria - anuria,
acute metabolic acidosis,
severe myasthenia gravis,
dehydration, Addison's disease,
arterial hypotension,
pregnancy,
lactation period,
age up to 18 years (efficacy and safety have not been established).
special instructions
No studies have been conducted to assess the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Name ENG
ASPARCAM
Clinical and pharmacological group
A drug that replenishes the deficiency of potassium and magnesium in the body
ATX code
Preparations of other mineral substances
Dosage
magnesium asparaginate 175 mg, potassium asparaginate 175 mg
Structure
1 tablet contains: active ingredients: magnesium asparaginate 175 mg, potassium asparaginate 175 mg.
Indications
To eliminate the deficiency of potassium and magnesium
as an aid for various manifestations of coronary heart disease, including acute myocardial infarction
chronic circulatory failure
heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).
Contraindications
Hypersensitivity to the drug Asparkam,
hyperkalemia,
hypermagnesemia,
acute and chronic renal failure,
insufficiency of the adrenal cortex,
atrioventricular block II and III degree,
cardiogenic shock,
oliguria - anuria,
acute metabolic acidosis,
severe myasthenia gravis,
dehydration, Addison's disease,
arterial hypotension,
pregnancy,
lactation period,
age up to 18 years (efficacy and safety have not been established).
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
INN / Active ingredient
magnesium asparaginate, potassium asparaginate
Specifications
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
56
Minimum age from
18 years
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Renewal
The amount of the dosage form in the primary package
8 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Potassium and magnesium drug
Anatomical and therapeutic characteristics
A12CX Other mineral preparations
Dosage form
Pills
Dosage (volume) of the substance in the preparation
magnesium asparaginate 175 mg, potassium asparaginate 175 mg
Expiration date in days
1095
Package weight, g
fifty
Category
:
Cardiovascular disorders
,
Arrhythmia
,
Balance potassium and magnesium
Mode of application
:
Inside, usually for adults - 1-2 tablets 3 times a day after meals.
The course of treatment is 3-4 weeks.
It can be repeated if necessary.